Siponimod

(Mayzent)

Siponimod

Drug updated on 11/14/2023

Dosage FormTablet (oral: 0.25 mg, 1 mg, 2 mg)
Drug ClassSphingosine 1-phosphate receptor modulators
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.